Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 32,012 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 70.9
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹ 2.00
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | |
| 695 | 666 | 628 | 914 | 1,174 | |
| Operating Profit | 408 | 565 | 429 | 505 | 671 |
| OPM % | 37% | 46% | 41% | 36% | 36% |
| 37 | 49 | 139 | 64 | 86 | |
| Interest | 17 | 10 | 7 | 10 | 10 |
| Depreciation | 62 | 58 | 64 | 82 | 89 |
| Profit before tax | 366 | 546 | 497 | 477 | 657 |
| Tax % | 26% | 26% | 23% | 23% | 31% |
| 271 | 406 | 385 | 367 | 451 | |
| EPS in Rs | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 4% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 114 | ||
| Reserves | 693 | 1,346 | 1,627 | ||
| 100 | 35 | 125 | |||
| 232 | 228 | 149 | |||
| Total Liabilities | 1,034 | 1,619 | 2,014 | ||
| 361 | 329 | 449 | |||
| CWIP | 19 | 154 | 164 | ||
| Investments | 209 | 273 | 499 | ||
| 445 | 863 | 902 | |||
| Total Assets | 1,034 | 1,619 | 2,014 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 278 | 333 | 306 | |||
| -196 | -205 | -376 | |||
| -63 | 181 | 64 | |||
| Net Cash Flow | 18 | 308 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 84 | 97 | 95 | ||
| Inventory Days | 29 | 52 | 139 | ||
| Days Payable | 50 | 50 | 77 | ||
| Cash Conversion Cycle | 63 | 99 | 156 | ||
| Working Capital Days | 53 | 84 | 123 | ||
| ROCE % | 51% | 27% |
Documents
Annual reports
No data available.
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.